RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE

Who May Qualify: - Age 50 years and older (no upper age limit) - Sustained a primary fragility fracture (hip/femur, pelvis, clinical spine, humerus, wrist) in the last 12 months - Participant must self-identify a regular primary care provider (PCP) - Participant must provide a mailing address - Participant must plan to remain geographically proximate (able to travel if necessary) to the site from which they are recruited over the next several months Who Should NOT Join This Trial: - Exposure to the following medications in the prior 12 months; - Actonel or Atelvia (risedronate) - Fosamax or Binosto (alendronate) - Reclast, Zometa, or Aclasta (zoledronic acid, zoledronate) - Boniva or Bondronat (ibandronate) - Aredia (pamidronate) - Prolia (denosumab) - Evenity (romozosumab) - Tymlos (abaloparatide) - Forteo (teriparatide) - Natpara (parathyroid hormone) - Evista (raloxifene) - Duavee (bazedoxifene-conjugated estrogen) - Miacalcin (calcitonin) - Diagnosis of the following medical conditions; - CKD stage 4 or 5 or on dialysis - Multiple myeloma - Addison's disease - Adrenal insufficiency - Enrolled hospice care - Solid organ transplant, or expecting a solid organ transplant - Bone marrow transplant - History of metabolic bone disease (except osteoporosis) such as Paget's disease, osteomalacia, osteogenesis imperfecta, or Cushing's disease - Fractures resulting from severe trauma (e.g. motor vehicle accidents, a fall from 2 feet or higher elevation) - Pathologic fractures secondary to malignancy or infection - Scheduled appointment with a bone health specialist - Participant unable to consent on their own (cognitive impairment, dementia, etc.) - Currently enrolled in another research study that requires taking medication Always talk to your doctor about whether this trial is right for you.